Gambaran Umum
Egetis Therapeutics AB, a biopharmaceutical company based in Sweden, specializes in the development and commercialization of orphan drugs and treatments for patients with rare diseases. A key focus for the company is its advanced clinical pipeline featuring projects such as Emcitate, a novel therapeutic designed for systemic sclerosis, and Aladote, aimed at reducing liver damage in paracetamol overdose patients. By leveraging their proprietary platform, Egetis aims to address significant unmet medical needs in niche markets, positioning themselves as innovators in the orphan drug sector. Their strategic approach combines targeted research and development with strong partnerships to facilitate the delivery of breakthrough treatments to market.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk Egetis Therapeutics AB (publ) per 2025 Jun 30 adalah 47.30 MM.
- Nilai operating income untuk Egetis Therapeutics AB (publ) per 2025 Jun 30 adalah -321.10 MM.
- Nilai net income untuk Egetis Therapeutics AB (publ) per 2025 Jun 30 adalah -337.20 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 47.30 | -321.10 | -337.20 |
2025-03-31 | 46.70 | -318.10 | -331.50 |
2024-12-31 | 46.10 | -321.80 | -343.60 |
2024-09-30 | 67.90 | -303.40 | -319.30 |
2024-06-30 | 70.80 | -299.70 | -319.40 |
2024-03-31 | 62.90 | -304.90 | -327.00 |
2023-12-31 | 57.60 | -311.30 | -326.90 |
2023-09-30 | 30.70 | -318.90 | -318.60 |
2023-06-30 | 23.70 | -287.90 | -286.10 |
2023-03-31 | 22.30 | -242.40 | -239.90 |
2022-12-31 | 22.60 | -197.00 | -193.80 |
2022-09-30 | 20.10 | -151.90 | -147.90 |
2022-06-30 | 20.98 | -116.13 | -112.96 |
2022-03-31 | 41.51 | -115.09 | -113.98 |
2021-12-31 | 38.20 | -105.20 | -104.50 |
2021-09-30 | 39.89 | -145.16 | -146.81 |
2021-06-30 | 36.28 | -149.85 | -152.68 |
2021-03-31 | 32.74 | -149.79 | -154.52 |
2020-12-31 | 40.66 | -177.06 | -178.02 |
2020-09-30 | 52.83 | -122.25 | -126.72 |
2020-06-30 | |||
2020-03-31 |
Laporan Laba Rugi: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | -1.12 | -1.10 |
2024-09-30 | -1.10 | -1.12 |
2024-06-30 | -1.14 | -1.20 |
2024-03-31 | -1.21 | -1.31 |
2023-12-31 | -1.27 | -1.30 |
2023-09-30 | -1.41 | -1.42 |
2023-06-30 | -1.29 | -1.29 |
2023-03-31 | -1.15 | -1.10 |
2022-12-31 | -1.00 | -1.00 |
2022-09-30 | -0.75 | -0.80 |
2022-06-30 | -0.61 | -0.60 |
2022-03-31 | -0.62 | -0.69 |
2021-12-31 | -0.58 | -0.60 |
2021-09-30 | -0.91 | -0.90 |
2021-06-30 | -1.17 | -1.14 |
2021-03-31 | -1.62 | -1.56 |
2020-12-31 | -2.64 | -2.60 |
2020-09-30 | -2.37 | -2.29 |
2020-06-30 | -2.50 | -2.56 |
2020-03-31 | -2.41 | -2.44 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Egetis Therapeutics AB (publ) per 2025 Jun 30 adalah -241.20 MM.
- Nilai cash from investing activities untuk Egetis Therapeutics AB (publ) per 2025 Jun 30 adalah -4.00 MM.
- Nilai kas dari aktivitas pendanaan untuk Egetis Therapeutics AB (publ) per 2025 Jun 30 adalah 256.70 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -241.20 | -4.00 | 256.70 |
2025-03-31 | -238.60 | -1.60 | 263.80 |
2024-12-31 | -227.90 | -1.20 | 270.90 |
2024-09-30 | -216.00 | 0.50 | 263.00 |
2024-06-30 | -246.60 | 262.90 | |
2024-03-31 | -254.30 | 263.00 | |
2023-12-31 | -278.40 | 458.90 | |
2023-09-30 | -299.10 | -0.50 | 193.60 |
2023-06-30 | -248.70 | 0.00 | 193.80 |
2023-03-31 | -219.80 | 0.00 | 353.90 |
2022-12-31 | -173.50 | -1.70 | 155.70 |
2022-09-30 | -137.10 | -3.00 | 153.80 |
2022-06-30 | -125.32 | -5.08 | 152.03 |
2022-03-31 | -128.29 | -6.38 | -9.76 |
2021-12-31 | -130.10 | -6.00 | -8.90 |
2021-09-30 | -143.12 | -64.24 | 221.97 |
2021-06-30 | -136.86 | -62.16 | 224.18 |
2021-03-31 | -132.53 | -60.86 | 226.42 |
2020-12-31 | -134.64 | -59.54 | 228.41 |
2020-09-30 | -124.33 | -0.21 | |
2020-06-30 | |||
2020-03-31 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/e untuk Egetis Therapeutics AB (publ) pada 2025 Jun 30 adalah -4.96.
- p/libro untuk Egetis Therapeutics AB (publ) pada 2025 Jun 30 adalah 3.79.
- p/tbv untuk Egetis Therapeutics AB (publ) pada 2025 Jun 30 adalah 3.82.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | -4.96 | 3.79 | 3.82 |
2025-03-31 | -3.82 | 2.66 | 2.68 |
2024-12-31 | -8.00 | 8.02 | 8.11 |
2024-09-30 | -5.31 | 4.23 | 4.27 |
2024-06-30 | -4.46 | 3.09 | 3.11 |
2024-03-31 | -4.82 | 2.88 | 2.91 |
2023-12-31 | -4.21 | 2.88 | 2.90 |
2023-09-30 | -4.69 | 2.44 | 2.46 |
2023-06-30 | -4.35 | 2.26 | 2.28 |
2023-03-31 | -5.19 | 1.98 | 2.00 |
2022-12-31 | -7.80 | 1.98 | 2.00 |
2022-09-30 | -7.23 | 1.84 | 1.85 |
2022-06-30 | -9.47 | 1.68 | 1.70 |
2022-03-31 | -7.22 | 1.65 | 1.67 |
2021-12-31 | -5.86 | 1.60 | 1.62 |
2021-09-30 | -5.43 | 1.48 | 1.50 |
2021-06-30 | -5.35 | 1.43 | 1.45 |
2021-03-31 | -5.29 | 1.35 | 1.36 |
2020-12-31 | -2.27 | 2.04 | 2.04 |
2020-09-30 | -2.27 | 2.04 | 2.04 |
2020-06-30 | -1.99 | 1.61 | 1.61 |
2020-03-31 | -2.10 | 1.32 | 1.32 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk Egetis Therapeutics AB (publ) pada 2025 Jun 30 adalah -0.23.
- EBIT (3 tahun) / EV untuk Egetis Therapeutics AB (publ) pada 2025 Jun 30 adalah -0.21.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -0.23 | -0.21 |
2025-03-31 | -0.32 | -0.28 |
2024-12-31 | -0.13 | -0.10 |
2024-09-30 | -0.20 | -0.16 |
2024-06-30 | -0.25 | -0.17 |
2024-03-31 | -0.24 | -0.15 |
2023-12-31 | -0.25 | -0.16 |
2023-09-30 | -0.25 | -0.16 |
2023-06-30 | -0.27 | -0.17 |
2023-03-31 | -0.24 | -0.17 |
2022-12-31 | -0.15 | -0.15 |
2022-09-30 | -0.17 | -0.16 |
2022-06-30 | -0.14 | -0.16 |
2022-03-31 | -0.16 | -0.18 |
2021-12-31 | -0.21 | -0.16 |
2021-09-30 | -0.23 | -0.17 |
2021-06-30 | -0.25 | -0.18 |
2021-03-31 | -0.27 | -0.19 |
2020-12-31 | -0.99 | -0.73 |
2020-09-30 | -0.99 | -0.73 |
2020-06-30 | -1.62 | -1.15 |
2020-03-31 | -2.78 | -1.93 |
Efektivitas Manajemen
- roa untuk Egetis Therapeutics AB (publ) pada 2025 Jun 30 adalah -0.51.
- roe untuk Egetis Therapeutics AB (publ) pada 2025 Jun 30 adalah -0.84.
- roic untuk Egetis Therapeutics AB (publ) pada 2025 Jun 30 adalah -0.61.
- croic untuk Egetis Therapeutics AB (publ) pada 2025 Jun 30 adalah 0.04.
- ocroic untuk Egetis Therapeutics AB (publ) pada 2025 Jun 30 adalah -0.44.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -0.51 | -0.84 | -0.61 | 0.04 | -0.44 |
2025-03-31 | -0.49 | -0.73 | -0.57 | 0.08 | -0.38 |
2024-12-31 | -0.60 | -0.68 | -0.74 | 0.10 | -0.50 |
2024-09-30 | -0.60 | -0.68 | -0.62 | 0.03 | -0.48 |
2024-06-30 | -0.48 | -0.52 | -0.55 | 0.01 | -0.43 |
2024-03-31 | -0.58 | -0.65 | -0.50 | 0.27 | -0.42 |
2023-12-31 | -0.52 | -0.55 | -0.68 | -0.22 | -0.64 |
2023-09-30 | -0.43 | -0.45 | -0.52 | -0.10 | -0.45 |
2023-06-30 | -0.36 | -0.45 | -0.51 | -0.10 | -0.45 |
2023-03-31 | -0.36 | -0.48 | -0.38 | 0.22 | -0.35 |
2022-12-31 | -0.19 | -0.27 | -0.25 | 0.03 | -0.23 |
2022-09-30 | -0.15 | -0.27 | -0.25 | 0.03 | -0.23 |
2022-06-30 | -0.14 | -0.20 | -0.18 | 0.04 | -0.20 |
2022-03-31 | -0.12 | -0.19 | -0.23 | -0.28 | -0.26 |
2021-12-31 | -0.92 | -1.07 | -0.27 | 0.02 | -0.26 |
2021-09-30 | -0.92 | -1.07 | -0.27 | 0.02 | -0.24 |
2021-06-30 | -0.80 | -0.93 | -0.26 | 0.04 | -0.24 |
2021-03-31 | -0.66 | -0.76 | -0.25 | 0.05 | -0.22 |
2020-12-31 | -0.44 | -0.47 | -0.90 | -0.90 | -0.88 |
2020-09-30 | -0.44 | -0.47 | -0.90 | -0.90 | -0.88 |
2020-06-30 | -0.41 | -0.45 | -0.81 | -0.81 | -0.81 |
2020-03-31 | -0.48 | -0.52 | -0.63 | -0.18 | -0.63 |
Gross Margins
- marjin kotor untuk Egetis Therapeutics AB (publ) pada 2025 Jun 30 adalah 0.60.
- marjin bersih untuk Egetis Therapeutics AB (publ) pada 2025 Jun 30 adalah -7.10.
- marjin operasi untuk Egetis Therapeutics AB (publ) pada 2025 Jun 30 adalah -6.81.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | 0.60 | -7.10 | -6.81 |
2025-03-31 | 0.75 | -7.45 | -7.15 |
2024-12-31 | -2.06 | -4.70 | -4.47 |
2024-09-30 | -1.92 | -4.51 | -4.36 |
2024-06-30 | -2.25 | -5.20 | -4.99 |
2024-03-31 | -2.55 | -5.68 | -5.64 |
2023-12-31 | -5.55 | -10.38 | -10.39 |
2023-09-30 | -7.01 | -12.07 | -12.14 |
2023-06-30 | -6.67 | -12.07 | -12.14 |
2023-03-31 | -5.31 | -10.76 | -10.87 |
2022-12-31 | -4.43 | -7.34 | -7.54 |
2022-09-30 | -2.89 | -7.34 | -7.54 |
2022-06-30 | -1.55 | -5.33 | -5.48 |
2022-03-31 | -1.52 | -2.74 | -2.76 |
2021-12-31 | -2.59 | -3.80 | -3.63 |
2021-09-30 | -3.05 | -3.80 | -3.63 |
2021-06-30 | -3.05 | -4.24 | -4.13 |
2021-03-31 | -3.50 | -4.75 | -4.58 |
2020-12-31 | -1.72 | -2.40 | -2.31 |
2020-09-30 | -1.72 | -2.40 | -2.31 |
2020-06-30 | -1.80 | -2.37 | -2.42 |
2020-03-31 | -2.45 | -3.23 | -3.39 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) |